NCT01505777

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea: Double Blinded, Randomized, Placebo Drug Controlled, Parallel Designed, Multi-centered, Phase 2 Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.

Conditions

• Irritable Bowel Syndrome Without Diarrhea

Interventions

Type	Name	Description
DRUG	Probiotics (Medirac)	10/mosapride 10mg three times a day, P.O. 4week
DRUG	Probiotics (Medirac)	15/mosapride 10mg three times a day, P.O. 4week
DRUG	Probiotics (Medirac)	15/mosapride 15mg three times a day, P.O. 4week
DRUG	Probiotics (Medirac)	30/mosapride 15mg three times a day, P.O. 4week
DRUG	Probiotics (Medirac) placebo/mosapride placebo	three times a day, P.O. 4week

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-01-09
• Last updated: 2013-04-05

Locations

1 site across 1 country: South Korea